Literature DB >> 31271496

miR-522 facilitates the prosperities of endometrial carcinoma cells by directly binding to monoamine oxidase B.

Hong-Chang Zhang1, Yan-Yan Han1, Xin-Min Zhang2, Nan Xiao1, Tao Jiang1, Shuang Zhu1, En-Peng Wang1, Chang-Bao Chen1.   

Abstract

It is well known that microRNAs (miRNAs) are crucial regulatory factors in tumorigenesis, as tumor suppressors or cancer-promoting factors. However, the study of endometrial carcinoma relevance in miR-522 is rare, indicating an undefined molecular mechanism for its role. Therefore, we performed this study to examine the role of miR-522 on the biological behaviors of endometrial carcinoma. In this work, we found that miR-522 was highly expressed in endometrial carcinoma and negatively regulated monoamine oxidase B (MAOB) expression. They also have the opposite effect on prognosis of endometrial carcinoma patients. More importantly, miR-522 could decreased MAOB expression by binding to MAOB with a putative site, thereby promoting cell proliferation, migration, and invasion through in vitro functional analyses, including MTT assay, wound-healing and transwell invasion experiments. Upregulation of MAOB rescued the impacts of miR-522 mimic on cell behaviors. In conclusion, our observations demonstrated that miR-522 accelerated the progression of endometrial carcinoma by inhibiting MAOB, which might lead to a novel therapeutic therapy for endometrial carcinoma.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  MAOB; cell behaviors; endometrial carcinoma; miR-522; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31271496     DOI: 10.1002/kjm2.12107

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  8 in total

1.  ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments.

Authors:  Rong Geng; Yuhua Zheng; Donghua Zhou; Qingdong Li; Ruiman Li; Xiaoling Guo
Journal:  Cancer Cell Int       Date:  2020-11-09       Impact factor: 5.722

2.  MicroRNA-15a-5p inhibits endometrial carcinoma proliferation, invasion and migration via downregulation of VEGFA and inhibition of the Wnt/β-catenin signaling pathway.

Authors:  Honggang Wang; Qingju Yang; Jieping Li; Wenping Chen; Xiao Jin; Yaowen Wang
Journal:  Oncol Lett       Date:  2021-02-22       Impact factor: 2.967

Review 3.  Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.

Authors:  Reem Aljanabi; Lina Alsous; Dima A Sabbah; Halise Inci Gul; Mustafa Gul; Sanaa K Bardaweel
Journal:  Molecules       Date:  2021-10-04       Impact factor: 4.411

4.  Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient.

Authors:  Jia Tang; Wei Ma; Liangping Luo
Journal:  Med Sci Monit       Date:  2019-11-03

Review 5.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

Review 6.  MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review.

Authors:  Amélia Favier; Grégoire Rocher; Annette K Larsen; Romain Delangle; Catherine Uzan; Michèle Sabbah; Mathieu Castela; Alex Duval; Céline Mehats; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2021-03-06       Impact factor: 6.639

7.  Targeting of ΔNp63α by miR-522 promotes the migration of breast epithelial cells.

Authors:  Yuanyuan Dong; Juan Long; Xingyong Luo; Gang Xie; Zhi-Xiong Jim Xiao; Ying Tong
Journal:  FEBS Open Bio       Date:  2021-01-10       Impact factor: 2.792

8.  CircZNF124 regulates cell proliferation, leucine uptake, migration and invasion by miR-199b-5p/SLC7A5 pathway in endometrial cancer.

Authors:  Liuping Shu; Yan Peng; Liyan Zhong; Xi Feng; Lifu Qiao; Yi Yi
Journal:  Immun Inflamm Dis       Date:  2021-06-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.